BBOT · BridgeBio Oncology Therapeutics, Inc.
AI read · Neutral
The AI's read
The lower target says Oppenheimer now sees less room for BBOT shares to rise. Keeping its Outperform rating points the other way. The report gives no new trial results or company changes, so it does not show a clear change in the company's prospects.